Crispr Therapeutics Ag (NASDAQ:CRSP) is one of the Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Biotech company Crispr ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) registers a bigger fall than the market: Important facts to note
CRISPR Therapeutics AG (CRSP) ended the recent trading session at $46.93, demonstrating a -1.59% change from the preceding day's closing price. This change lagged the S&P 500's 0.28% loss on the day.
CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the top gene therapy stocks to buy according to hedge funds. On February 17, ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) falls more steeply than broader market: What investors need to know
CRISPR Therapeutics AG (CRSP) closed at $47.69 in the latest trading session, marking a -4.79% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 1.36%. Elsewhere ...
CRISPR Therapeutics reached a significant milestone a couple of years ago: its first product approval. The company’s stock, once a highflier, has declined from its peak. CRISPR Therapeutics (NASDAQ: ...
CRISPR Therapeutics had its first FDA-approved product in December 2023, a treatment for sickle cell disease called Casgevy. It’s also developing treatments for cancer and cardiovascular disease using ...
CRISPR Therapeutics has some promising and innovative pipeline candidates. The stock will soar if it can execute and deliver strong clinical and regulatory progress. CRISPR Therapeutics has lagged the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results